Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES.
Szarek M, Reijnders E, Steg PG, Jukema JW, Schwertfeger M, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, White HD, Zeiher AM, Cobbaert C, Schwartz GG.
Szarek M, et al. Among authors: fazio s.
Eur J Prev Cardiol. 2024 Mar 19:zwae110. doi: 10.1093/eurjpc/zwae110. Online ahead of print.
Eur J Prev Cardiol. 2024.
PMID: 38501249
No abstract available.